SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Messenger RNA or mRNA strand 3D rendering illustration with copy space. Genetics, science, medical research, genome replication concepts.
Government
Despite mRNA Vaccine Pullback, HHS Awards $48M for Kernal’s mRNA CAR T Program
The $48 million award, granted through the Advanced Research Projects Agency for Health, will help Kernal take its in vivo mRNA-encoded CAR T therapy forward.
October 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
The U.S. government remains shut down, with the FDA closed for new drug applications until further notice; cell and gene therapy leaders gather for the annual meeting in Phoenix with the field in a state of flux; Pfizer and Amgen will make drugs available at a discount as President Donald Trump’s tariffs still loom; and new regulatory documents show how Pfizer beat out the competition for Metsera.
October 8, 2025
 · 
1 min read
 · 
Heather McKenzie
Abstract illustration of targeting cancer cell made of glowing neon particles. Blue geometric background depicting cancer cell screening and disease treatment medical concept. Digital vector illustration
Cell therapy
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.
October 8, 2025
 · 
2 min read
 · 
Annalee Armstrong
3D collage design composite trend artwork sketch of different routeway direction target trader young lady back walk step success choice.
C-suite
The 5 Most Powerful Women in Biopharma
As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the industry’s smaller biopharmas.
October 8, 2025
 · 
6 min read
 · 
Annalee Armstrong
Business time plan concept and planning corporate or personal schedule or wasting minutes as a group of timepieces or clocks coming out of a large clock as a 3D illustration.
Opinion
Drug Price Critiques Ignore a Crucial Consideration—Time
Drug pricing criticism often fixates on a price at a single point in time but drug pricing is never static.
October 8, 2025
 · 
3 min read
 · 
Melanie Whittington
Regulatory
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator
Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.
October 7, 2025
 · 
1 min read
 · 
Heather McKenzie
a hand with a lit match lighting another match
IPOs
UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio
MapLight laid out the terms of its planned IPO in a regulatory filing on Monday, providing greater detail about what the funds will be used for.
October 7, 2025
 · 
3 min read
 · 
Tristan Manalac
Auction concept: Hands holding paddle with numbers
Mergers & acquisitions
Pfizer Beat Out Two Other Metsera Suitors for Takeover
Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.
October 7, 2025
 · 
3 min read
 · 
Tristan Manalac
Connecting puzzle pieces. Art collage.
Obesity
Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail
Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.
October 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS